US 12,252,532 B2
Anti-myostatin antibodies and methods of use
Yoshinao Ruike, Singapore (SG); and Taichi Kuramochi, Singapore (SG)
Assigned to CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on May 12, 2022, as Appl. No. 17/742,824.
Application 17/742,824 is a division of application No. 16/065,192, granted, now 11,359,009, previously published as PCT/JP2016/088302, filed on Dec. 22, 2016.
Claims priority of application No. 2015-253346 (JP), filed on Dec. 25, 2015.
Prior Publication US 2022/0275076 A1, Sep. 1, 2022
Int. Cl. C07K 16/22 (2006.01); A61K 39/00 (2006.01); A61P 21/00 (2006.01)
CPC C07K 16/22 (2013.01) [A61P 21/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 6 Claims
 
1. A method of producing an antibody, the method comprising:
preparing a nucleic acid encoding an antibody that binds to mature myostatin homodimer having the amino acid sequence of SEQ ID NO:2; and
culturing an isolated host cell comprising the nucleic acid so that the antibody is produced,
wherein the antibody has been determined to have at least 2.5-fold higher cellular uptake compared with a reference antibody which is identical to the antibody except that the Fc region of the reference antibody has no Fc gamma receptor-binding activity, and
wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence X1YVX2G, wherein X1 is N or H, X2 is M or K (SEQ ID NO: 84), (b) HVR-H2 comprising the amino acid sequence IINIX1GX2TYYASWAX 3G, wherein X1 is S or E, X2 is S or E, X3 is K or E (SEQ ID NO: 85), (c) HVR-H3 comprising the amino acid sequence GX1DNFGYSYX2DFNL, wherein X1 is G or H, X2 is I or H (SEQ ID NO: 86), (d) HVR-L1 comprising the amino acid sequence QASX1SIX2X3X4LS, wherein X1 is Q or E, X2 is S or H, X3 is N or H, X4 is E or D (SEQ ID NO: 87); (e) HVR-L2 comprising the amino acid sequence LASTLAS (SEQ ID NO: 81); and (f) HVR-L3 comprising the amino acid sequence QTYDGISX1YGVA, wherein X1 is S or H (SEQ ID NO: 88).